A carregar...
Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials
AIM: To assess the lipid‐lowering efficacy and safety of alirocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in people with hypercholesterolaemia and prediabetes at baseline vs people with normoglycaemia at baseline in a pooled analysis of 10 ODYSSEY phase III trials. METH...
Na minha lista:
| Publicado no: | Diabet Med |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5763418/ https://ncbi.nlm.nih.gov/pubmed/28799203 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dme.13450 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|